Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: Cost drivers and cost savings

Rheumatology

Volumn 50, Issue 4, 2011, Pages 756-761

  Kirchhoff, Timm ^a   Ruof, Jörg ^a   Mittendorf, Thomas ^b,c   Rihl, Markus ^a   Bernateck, Michael ^a   Mau, Wilfried ^d   Zeidler, Henning ^a,e   Schmidt, Reinhold E ^a   Merkesdal, Sonja ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c Herescon GmbH Health Economic Research and Consulting   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e Rheumatologikum Hannover   (Germany)

Author keywords

Cost savings; Cost of illness; Disease modifying drugs; Rheumatoid arthritis; Tumour necrosis factor inhibitors

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DRIVER; FEMALE; GASTROINTESTINAL TRACT; GERMANY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROTECTION; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; EFFICIENCY; FEMALE; GERMANY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952779676     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq398     Document Type: Article

References (22)

1. Kavanaugh A. Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 2007;21:929-42.
2. Merkesdal S, Ruof J, Mittendorf T, Mau W, Zeidler H. [Health economic research in the field of rheumatoid arthritis]. Z Rheumatol 2002;61:21-9.
3. Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum 2007;56:1397-407.
4. Mau W, Bornmann M, Weber H, Weidemann HF, Hecker H, Raspe HH. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis. Br J Rheumatol 1996;35:652-9.
5. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis. Arthritis Rheum 2001;44:528-34.
6. Ruof J, Hulsemann JL, Mittendorf T et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-9.
7. Hulsemann JL, Mattussek S, Hennig H, Stucki G. [Quality management of treatment of rheumatoid arthritis in a rheumatological setting.]. Z Arztl Fortbild Qualitatssich 2003;97:383-90.
8. Ruof J, Merkesdal S, Huelsemann JL et al. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics. J Rheumatol 2001;28: 662-5.
9. Merkesdal S, Ruof J, Huelsemann JL et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001;28:657-61.
10. Schulenburg JM, Greiner W, Jost F et al. The Hanover Consensus Group. German recommendations on health economic evaluation. Value Health 2008;11:539-44.
11. Ruof J, Huelsemann JL, Mittendorf T et al. Patient-reported health care utilization in rheumatoid arthritis: what level of detail is required? Arthritis Rheum 2004;51:774-81.
12. Einheitlicher Bewertungsmaßstab für ärztliche Leistungen [Uniform value scale for physician services]. Kassenärztliche Bundesvereinigung Berlin. http://www .kbv.de/8156.html (1 November 2010, date last accessed).
13. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14:171-89.
14. Brouwer WB, Koopmanschap MA. The friction-cost method: replacement for nothing and leisure for free? Pharmacoeconomics 2005;23:105-11.
15. Statistisches Bundesamt. Statistical Yearbooks for the Federal Republic of Germany. Wiesbaden: Metzler Poeschel, 2003.
16. Lautenschläger J, Mau W, Kohlmann T et al. Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire. Z Rheumatol 1997;56:144-55.
17. Sany J, Cohen JD, Combescure C et al. Medicoeconomic evaluation of infliximab in rheumatoid arthritis-prospective French study of a cohort of 635 patients monitored for two years. Rheumatology 2009;48: 1236-41.
18. Bejarano V, Quinn M, Conaghan PG et al. Yorkshire Early Arthritis Register Consortium: effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
19. Manger B, Michels H, Nüsslein HG, Schneider M, Sieper J. [Guidelines of the German Society of Rheumatology for employment of tumor necrosis factor-blocking substances.] March 2006.
20. Zink A, Huscher D, Schneider M. [The National Database of the German Arthritis Centres-a 12 year balance]. Z Rheumatol 2006;65:144, 146-51.
21. Mittendorf T, Edelmann E, Kekow J et al. Current status and perspectives of ambulatory rheumatologic health care in Germany: economic structural conditions and motivation of rheumatologists. Z Rheumatol 2007;66: 611-20.
22. Mittendorf T, Edelmann E, Kekow J et al. Current status of ambulatory rheumatologic health care in Germany. Structure of health care and range of services. Z Rheumatol 2007;66:525-32.